# Critique: finding-1

- Target Side: side_b
- Target Claim IDs: side_b-claim-1, side_b-claim-3
- Attack Type: evidence_gap
- Severity: high

## Claim Under Attack
A staged pricing approach is preferable to an immediate broad price increase when market data is incomplete, and the organization is only ready for a test-led strategy until missing evidence is gathered.

## Evidence Or Reason
Side B presents 'stage and test' as the lower-risk default without examining the cost of delay. Under partial data, inaction is also a bet: it assumes the current price point is not already leaving significant revenue on the table, that competitors will not reprice first and anchor customer expectations, and that the organization can afford the elapsed time and operational cost of experimentation before capturing upside. None of these assumptions are supported by evidence — the artifact cites zero evidence refs for all three major claims. Furthermore, the readiness verdict ('conditionally pass for staged test') quietly depends on pass conditions (baseline metrics, isolable cohorts, instrumentation) that the artifact itself flags as unknown. If those conditions are not met — which the evidence gaps strongly suggest — the strategy collapses to 'do nothing until you can do something,' which is not a recommendation but an indefinite deferral. A decision-useful artifact must quantify the cost of waiting versus the cost of acting under uncertainty, not simply assert that waiting is safer.

